BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 26, 2015
 |  BioCentury  |  Emerging Company Profile

Cloaking conjugates

How Blend's Pentarins may deliver better efficacy than standard ADCs

After spending its first 18 months using medicinal chemistry to discover novel platinum-based cytotoxic agents for cancer, Blend Therapeutics Inc. has decided to branch out into developing a biologic-drug conjugate platform that may provide greater efficacy than traditional antibody-drug conjugates with longer half-lives than conjugates based on smaller protein scaffolds.

The company unveiled its Pentarin platform this month, along with a fresh infusion of capital from a series B extension, after in-licensing exclusive rights to a bipodal biologic targeting ligand technology from an undisclosed biotech. Chairman Omid Farokhzad said the deal brought in house the last piece of the puzzle for the platform.

Pentarins are small biologic targeting ligands conjugated to cytotoxic payloads, which are then encapsulated within a nanoparticle.

According to President...

Read the full 619 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >